BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Concentrations

Concentrations

9 Months Ended

Sep. 30, 2022

Risks and Uncertainties [Abstract]

Concentrations

NOTE 13—CONCENTRATIONS

Revenue from the Company’s products are as follows (dollars in thousands):


	Three Months Ended								Nine Months Ended
	September 30,								September 30,
	2022				2021				2022				2021
Laser systems	$	7,302	60.8	%	$	6,084	63.8	%	$	21,626	62.9	%	$	16,588	61.9	%
Consumables and other		2,632	21.9	%		2,331	24.5	%		8,379	24.3	%		6,923	25.9	%
Services		2,076	17.3	%		1,116	11.7	%		4,406	12.8	%		3,269	12.2	%
Total net revenue	$	12,010	100.0	%	$	9,531	100.0	%	$	34,411	100.0	%	$	26,780	100.0	%

No individual customer represented more than 10% of the Company’s revenue for the three and nine months ended September 30, 2022 or 2021.

The Company maintains its cash and cash equivalents in money market investment accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

No individual customer represented more than 10% of the Company’s accounts receivable at September 30, 2022 and December 31, 2021.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations and financial condition.